{"id":"plb1004","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without publicly available detailed mechanism information, PLB1004's exact target and mode of action cannot be reliably specified. As a Phase 3 asset from Avistone Biotechnology, it is likely a targeted therapeutic, but the specific molecular target and therapeutic mechanism require access to clinical trial data or company disclosures.","oneSentence":"PLB1004 is a small molecule inhibitor targeting a specific molecular pathway in cancer or immune-related disease.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:29:18.610Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07336732","phase":"PHASE2","title":"Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2026-03-11","conditions":"Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT07285148","phase":"PHASE1, PHASE2","title":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2026-06","conditions":"Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer","enrollment":253},{"nctId":"NCT06281964","phase":"PHASE3","title":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","status":"ENROLLING_BY_INVITATION","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2023-12-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":327},{"nctId":"NCT07063329","phase":"PHASE1, PHASE2","title":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","status":"NOT_YET_RECRUITING","sponsor":"Avistone Pharmaceutical（Ningbo）Co., LTD.","startDate":"2025-08-08","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":108},{"nctId":"NCT06343064","phase":"PHASE1, PHASE2","title":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2023-06-13","conditions":"Non-Small-Cell Lung Cancer","enrollment":156},{"nctId":"NCT06970782","phase":"PHASE3","title":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure","status":"NOT_YET_RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2025-05-15","conditions":"Non-Small-Cell Lung Cancer","enrollment":278},{"nctId":"NCT06574347","phase":"PHASE2","title":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2024-08-07","conditions":"Non-Small-Cell Lung Cancer","enrollment":120},{"nctId":"NCT06046495","phase":"PHASE1","title":"A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2024-07-08","conditions":"Non-Small Cell Lung Cancer","enrollment":81},{"nctId":"NCT06015503","phase":"PHASE2","title":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2023-07-21","conditions":"Non-Small-Cell Lung Cancer","enrollment":157},{"nctId":"NCT05347628","phase":"PHASE1","title":"Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2020-08-25","conditions":"Non-Small-Cell Lung Cancer","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Andamertinib"],"phase":"phase_3","status":"active","brandName":"PLB1004","genericName":"PLB1004","companyName":"Avistone Biotechnology Co., Ltd.","companyId":"avistone-biotechnology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}